How Are European Biotechs Tackling the Cardiovascular Disease Problem?
Cardiovascular diseases may not regularly grab the headlines, but they’re the leading cause of mortality…
Cardiovascular diseases may not regularly grab the headlines, but they’re the leading cause of mortality…
The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled…
A once forgotten technology, RNA editing has been gaining traction as a treatment for genetic…
AstraZeneca is recruiting RNAi specialist Silence Therapeutics to develop treatments for cardiovascular, renal, metabolic, and…
US biotech Alnylam Pharmaceuticals has succeeded in getting its second RNAi drug -- for treatment…
RNA vaccine developer CureVac will receive a grant of up to €8.3M from a global…
The UK biotech MiNA Therapeutics has launched a collaboration with AstraZeneca to develop small activating…
A CAR T-cell therapy amplified by RNA technology, developed by BioNTech, has shown preclinical potential…
With the year coming to a close, it’s time to review the most important biotech…
Novartis is to acquire The Medicines Company and its late-stage RNA interference drug designed to…
The first RNA interference therapy was approved in 2018, after 20 years in development. What…
A phase I/II trial run by the Dutch company ProQR has found that its RNA…